Direct anabolic metabolism of three-carbon propionate to a six-carbon metabolite occurs in vivo across tissues and species

Mary T. Doan¹, Michael D. Neinast², Erika L. Varner¹, Kenneth C. Bedi Jr.², David Bartee §, Helen Jiang¹, Sophie Trefely¹,², Peining Xu³, Jay P. Singh¹, Cholsoon Jang¹, J. Eduardo Rame², Donita C. Brady §, Jordan L. Meier³, Kenneth B. Marguelles³, Zoltan Arany §, and Nathaniel W. Snyder §,*¹

¹Center for Metabolic Disease Research, Department of Cardiovascular Sciences, Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA; ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; ³Chemical Biology Laboratory, National Cancer Institute, Frederick MD, USA; ⁴Lewis Sigler Institute for Integrative Genomics and Department of Chemistry, Princeton University, Princeton, NJ, USA

Abstract Anabolic metabolism of carbon in mammals is mediated via the one- and two-carbon carriers S-adenosyl methionine and acetyl-coenzyme A. In contrast, anabolic metabolism of three-carbon units via propionate has not been shown to extensively occur. Mammals are primarily thought to oxidize the three-carbon short chain fatty acid propionate by shunting propionyl-CoA to succinyl-CoA for entry into the TCA cycle. Here, we found that this may not be absolute as, in mammals, one nonoxidative fate of propionyl-CoA is to condense to two three-carbon units into a six-carbon trans-2-methyl-2-pentenoyl-CoA (2M2PE-CoA). We confirmed this reaction pathway using purified protein extracts provided limited substrates and verified the product via LC-MS using a synthetic standard. In whole-body in vivo stable isotope tracing following infusion of ¹³C-labeled valine at steady state, 2M2PE-CoA was found to form via propionyl-CoA in multiple murine tissues, including heart, kidney, and to a lesser degree, in brown adipose tissue, liver, and tibialis anterior muscle. Using ex vivo isotope tracing, we found that 2M2PE-CoA also formed in human myocardial tissue incubated with propionate to a limited extent. While the complete enzymology of this pathway remains to be elucidated, these results confirm the in vivo existence of at least one anabolic three- to six-carbon reaction conserved in humans and mice that utilizes propionate.

Supplementary key words Metabolism • propionate • anabolism • acetyl-CoA • condensation reaction • 2M2PE-CoA • stable isotope tracing • LC-MS/HRMS • TCA cycle • valine

One- and two-carbon (1C and 2C) metabolism are highly conserved metabolic processes for anabolic and catabolic biotransformation. 1C metabolitism is facilitated via folate intermediates, with a formyl-group transferred through activated intermediates including S-adenosyl methionine (1). 2C metabolism occurs primarily via the formation of the thioester acetyl-coenzyme A (acetyl-CoA) and transfer of the activated acetyl-group from the thioester to substrates (2, 3). Both 1C and 2C metabolic pathways are conserved across bacteria, yeast, plants, and animals. In contrast, direct anabolic three-carbon (3C) metabolism is thought to occur in a more limited set of organisms, including in propionic bacteria (4) and in metabolism of branched chain hydrocarbons and hormones in some insects (5). It is generally thought that mammals do not use 3C intermediates directly for anabolic reactions, with the notable exception of pyruvate as a gluconeogenic substrate (6). In propionate-mediated 3C metabolism, propionyl-CoA, the CoA thioester of propionic acid, functions as the central metabolic intermediate. For instance, propionyl-CoA is an intermediate in the catabolism of two branched amino acids, isoleucine and valine (7). Propionyl-CoA can also be formed from catabolism of diverse substrates including odd-chain fatty acids, cholesterol, C-5 ketone bodies, threonine, and methionine (5). Since it is energetically unfavorable to metabolize propionyl-CoA via β-oxidation, the canonical use of propionyl-CoA is for anaplerosis into the TCA cycle by metabolism to succinyl-CoA via D- then L-methylmalonyl-CoA (8, 9).

Propionate metabolism in humans results in unique biochemical effects with mostly unknown mechanisms of action. Infusion or feeding of propionate causes perturbations of liver metabolism in rodents, dogs, and humans (10, 11). Extreme pathological defects in propionate metabolism including propionic acidemia (PA), an inherited disorder caused by an aberrant function of propionyl-CoA carboxylase, result in significant morbidity and mortality (12) and systemic metabolic
dysregulation (13). Although PA is often detectable by newborn screening, even after diagnosis, prognosis remains poor due to subclinical metabolic dysregulation, life-threatening metabolic decompensations, and sequelae from severe crisis (14). Especially during these metabolic crisis, patients with PA have high levels of organic acids and acylcarnitines in the blood and urine which include not only propionic acid/propionylcarnitine but also a wider dysregulated metabolome of mostly unidentified metabolites (15). This suggests that propionate can be metabolized to a wide number of poorly described products in vivo. The relevance of these metabolites to normal physiology with lower levels of circulating propionate is unknown. Furthermore, since anaplerosis to the TCA cycle is tightly regulated, the nonoxidative fates of propionyl-CoA that is not shunted through succinyl-CoA is unclear.

Recently, we described a potential route for anabolic 3C metabolism in cell culture and ex vivo platelets to convert propionyl-CoA into the acyl-CoA thioester of trans-2-methyl-2-pentenoic acid (2M2PE), a 6-carbon compound that retained all of the carbons from two monomeric units of propionate (16). This contrasts with the monomethyl branched chained fatty acids synthesis in mammalian adipose tissues, which requires 2C metabolism via acetyl-CoA (17). However, the existence of this pathway in intact tissues and more physiologically relevant systems remained unknown. Here, we confirmed this pathway by using purified protein extracts and a limited set of substrates, and we compared the product against a synthetically prepared standard. We then tested the existence of this pathway in vivo in mice using an infusion of U-13C-valine which maintains three labeled atoms in catabolism to propionyl-CoA (Fig. 1) (18). Steady state infusion of valine in awake and mobile rodents was chosen for physiological relevance to avoid induction of artificial metabolism from supraphysiological propionate concentrations while maintaining normal oxidative uses of propionyl-CoA. Finally, we examined the formation of 2M2PE-CoA from 13C3-propionate ex vivo using a mismatched human donor heart.

MATERIALS AND METHODS

Materials and reagents

[13C3]-sodium propionate was purchased from Cambridge Isotopes (Tewksbury, MA). 5-sulfosalicylic acid (SSA), trichloroacetic acid, and ammonium acetate were purchased from Sigma-Aldrich (St. Louis, MO). Optima LC-MS grade methanol (MeOH), acetonitrile (ACN), formic acid, and water were purchased from Fisher Scientific (Pittsburgh, PA).

Synthesis of 2-methyl-2-pentenoyl-CoA

Synthesis was conducted as previously described with modifications (19). Briefly, diisopropylethylamine (0.12 ml, 0.70 mmol) was added to a solution of 2M2PE (30.6 ml, 0.26 mmol) in dichloromethane (2 ml) cooled to 0 °C. Isobutyl chloroformate (64 μl, 0.65 mmol) was added at 0 °C with stirring. The resulting solution was allowed to warm to 22 °C and stirred for an additional 2 h, after which, volatiles were removed under reduced pressure to provide a colorless residue. Tetrahydrofuran (THF, 1 ml) was added to the residue resulting in the precipitation of diisopropylethylammonium
chlore. This mixture was transferred to a 1.6 ml conical tube and centrifuged to pellet the solid. The THF solution was added to a solution of coenzyme A (30 mg, 0.039 mmol) in aqueous bicarbonate solution (1 ml, 500 mM, pH 8). The biphasic mixture was stirred vigorously at 22 °C. After 3 h, stirring was stopped and THF was evaporated under a stream of N2. The remaining aqueous solution was neutralized with trifluoroacetic acid (20 ml) and immediately purified by C18-reversed phase-silica chromatography. Method: (solvents - A: 0.05% trifluoroacetic acid in water, B: acetonitrile) gradient - 0 - 2 column volumes (CV), 0% B; 2-12 CV, 0%-50% B; 12-13 CV, 50%-100% B; and 13-25 CV, 100% B. Fractions containing the desired product were pooled and lyophilized to provide a fluffy white powder (17.7 mg, 52.5% yield). 1H NMR (500 MHz, D2O) δ 8.63 (s, 1H), 8.42 (d, J = 3.2 Hz, 1H), 6.77 (t, J = 7.2 Hz, 1H), 6.18 (d, J = 5.7 Hz, 1H), 4.91 (s, 1H), 4.89 - 4.84 (m, 1H), 4.60 (s, 1H), 4.35 - 4.19 (m, 2H), 4.01 (s, 1H), 3.89 (d, J = 9.1 Hz, 1H), 3.65 (d, J = 9.2 Hz, 1H), 3.44 (t, J = 6.8 Hz, 2H), 3.35 (t, J = 6.5 Hz, 2H), 2.99 (t, J = 6.3 Hz, 2H), 2.43 (q, J = 6.3 Hz, 2H), 2.19 (p, J = 7.5 Hz, 2H), 1.77 (s, 2H), 0.99 (t, J = 7.6 Hz, 3H), 0.94 (s, 3H), 0.82 (s, 3H). HRMS (ESI) calculated for C27H44N7O17P3S+ [M + H]+ = 864.1800 found 864.1811. 2M2PE-CoA was added as Lipidmaps CID: 121225619.

Protein purification and enzyme assay

Cells were passaged every 2–3 days at 80% confluency. Human hepatocellular carcinoma (HepG2) cells were cultured in high glucose DMEM (Thermo-Fisher Scientific) and supplemented with 10% fetal bovine serum (Gemini Biosciences) and penicillin/streptomycin (Thermo Fisher Scientific) and supplemented with 10% fetal bovine serum (Gemini Biosciences) and penicillin/streptomycin (Thermo Fisher Scientific). SILEC labeling of HepG2 cells was achieved as previously described (20). As positive controls, 2M2PE-CoA was generated in cell culture, as previously described (16), by treating HepG2 cells for 1 h with either 100 μM propionate, [13C3]-propionate, or 2M2PE. Following the incubation, the acyl-CoA thioesters were extracted and analyzed.

To obtain purified protein, approximately 3 × 10⁶ HepG2 cells were collected and lysed by shaking in 500 μl of ice-cold FPLC buffer (50 mM Tris-HCl pH: 7.5, 150 mM NaCl, 100 mM KCl, 1% NP-40 and 1% Glycerol) for 5 min. The cell debris was pelleted by centrifugation at 17,000 g 4 °C for 5 min. The 3 mg/ml protein sample was injected onto NGC Liquid Chromatography System (Biorad) equipped with a HiPrep Sephacryl S-500 HR column equilibrated in FPLC buffer and separated into 156, 1 ml fractions. A 290 μl aliquot of each protein fraction was incubated at 37 °C for 2 h with 100 μl of the FPLC buffer containing propionyl-CoA (100 μM), NADH (1 mM), and NADPH (1 mM). Absorbance was recorded at 260 nm and 340 nm before and after the 2-h incubation. Following the incubation, the acyl-CoA thioesters were extracted and analyzed.

Tissue studies

As described previously (18), [13C]-valine infusion was performed on 12-week old male (C57/blk6) or db/db mice with a catheter surgically implanted on the right jugular vein. The mouse infusion setup included a tether and swivel system which permitted the mice to have free movement in the cage with bedding materials and free access to water. Briefly, the mice fasted for 5 h and then infused intravenous (i.v.) with [U-13C]-valine at ~20% of the endogenous rate of appearance for 120 min to achieve steady state labeling. Unlabeled leucine and isoleucine were also infused with the labeled valine. Mice were sacrificed by pentobarbital injection followed by immediate cervical dislocation, and tissues were quickly harvested and snap-frozen within 1.5 min of cervical dislocation. Frozen brown adipose tissue (BAT), heart, kidney, liver, tibialis anterior muscle (TA), and gonadal white adipose tissue (gWAT) were individually cut on dry ice. Tissue samples were weighed to aliquots between 7 to 16 mg in 1.5 ml Eppendorf tubes then taken for extraction and analysis in conditions identical to those used for heart tissues. All animal work was approved by the University of Pennsylvania Institutional Animal Care and Use Committee.

Procurement of human myocardial tissues came from a healthy male donor on no medications and had no positive serologies. The decedent was 52 years old, weighed 90 kg, 175 cm tall with a body mass index of 29.3 and body surface area of 20.9. Patient’s heart (352 g, left ventricle mass 213 g) displayed normal values of echocardiographic measurements. There were also no troponin leaks suggesting no ischemia. However, patient was turned down from transplantation due to a 50%-60% stenotic left anterior descending coronary artery (seg 6) and died from a cerebrovascular accident/stroke of the middle cerebral artery. Otherwise, the donated heart was considered healthy enough to reflect normal human physiology. Heart tissues from a section of the left ventricle wall were individually cut over dry ice and weighed to aliquots between 40 to 55 mg in 1.5 ml Eppendorf tubes. For time course studies, prewarmed 1 ml of 100 μM [13C3]-sodium propionate in Tyrode’s buffer with 5 mM glucose was added to each sample then incubated at 37 °C for 15, 30, and 60 min. Samples were centrifuged at 10,000 g for 2 min at 4 °C to pellet the tissues. The resulting pellet was extracted and analyzed.

Extraction of acyl-CoAs

Extractions for short chain acyl-CoAs were performed as previously described (16). Briefly, 1 ml of ice-cold 10% (w/v) trichloroacetic acid was added to tissues preweighed in a 1.5 ml Eppendorf tube, 50 μl of mixed acyl-CoA internal standard generated as previously described (20) was added, then the sample was vortexed 5 s to mix. With a probe tip sonicator (Fisher), samples were homogenized and dismembranated by 12 × 0.5 s pulses and centrifuged at 15,000 g for 10 min at 4 °C. The supernatant was purified by a solid-phase extraction on Oasis HLB Icc (30 mg) solid-phase extraction columns (Waters). Columns were preconditioned with 1 ml MeOH then 1 ml water, 1 ml of sample was loaded, the column was washed with 1 ml water, and then the eluate was collected into glass tubes using 1 ml of 25 mM ammonium acetate in MeOH. Eluates were evaporated to dryness under nitrogen gas and resuspended in 50 μl of 5% (w/v) sulfosalicylic acid. Injections of 5 μl were made for LC-HRMS analysis.

LC-HRMS and LC-MS/HRMS analysis

Sample analysis was performed as previously described (21). Briefly, acyl-CoAs were analyzed using an Ultimate 3000 Quaternary UHPLC coupled to a Q Exactive Plus mass spectrometer operating in the positive ion mode with a heated electrospray ionization mark II (HESI-II) probe in an Ion Max spectrometer. Source housing. Samples were kept in a temperature-controlled autosampler at 6 °C. Acyl-CoA separation was accomplished by a Waters HSS T3 2.1 × 150 mm column using a three solvent system: (A) 5 mM ammonium acetate in water; (B) 5 mM ammonium acetate in 95/5 ACN/water (v/v/v); and (C) 80/20/0.1 ACN/water/formic acid (v/v/v), with a constant
flow rate of 0.2 ml/min. Gradient performance was as follows: 98% A and 2% B for 1.5 min, 80% A and 20% B at 5 min, and 100% B at 12 min; 0.5 ml/min flow at 100% B at 16 min; and 0.2 ml/min flow at 100% C at 17 min, held to 21 min, then reequilibrated at 0.2 ml/min flow at 98% A and 2% B from 22 to 28 min. Flow from 4 to 18 min was diverted to the instrument. The mass spectrometer operating conditions were as follows: auxiliary gas 10 arbitrary units (arb), sheath gas 35 arb, sweep gas 2 arb, spray voltage 4.5 kV, capillary temperature 425 °C, S-lens RF level 50, auxiliary gas heater temperature 400 °C, and in-source CID 5 eV. Scan parameters conditions were alternating full scan from 760 to 1800 m/z at 140,000 resolution and data-independent acquisition looped three times with all fragment ions multiplexed at a normalized collision energy of 20 at a resolution of 280,000. An isolation width of 7 m/z with an offset of 3 m/z was used to capture all relevant isotopologs for targeted acyl-CoA thioesters. Data was processed in Xcalibur 3.0 Quan Browser and TraceFinder 4.1 (Thermo), and statistical analysis was conducted in Excel 2016 (Microsoft) and GraphPad Prism software (v7) (GraphPad, La Jolla, CA). Relative abundance and isotopolog percentage were calculated for each metabolite. Relative abundance of acyl-CoA metabolites was calculated as the sum of the area of all measured isotopologs/the area of the internal standard. For acyl-CoAs where a standard was available, the ratio of the area of all measured isotopologs/the area of the internal standard was used to generate standard curves which were linear and sample values were interpolated from this curve. Isotopolog enrichment (%) was computed using Fluxfix (http://fluxfix.science), a free web-based calculator (22) using unlabeled samples for experimental isotopic correction.

RESULTS

2M2PE-CoA can be generated via purified protein extracts using propionyl-CoA and reducing equivalents

Previously, we demonstrated that treating HepG2 cells with propionate creates a dose- and time-dependent formation of 2M2PE-CoA (16). To confirm the pathway of 2M2PE-CoA production, HepG2 protein extracts were purified using FPLC separation and incubated for 2 h with 100 μM propionyl-CoA, 1 mM NADH, and 1 mM NADPH. Of the 156 FPLC fraction collected, samples 90–100 converted propionyl-CoA into 2M2PE-CoA as confirmed by the production of both the 2M2PE-CoA product and a putative intermediate, 3-hydroxy-2-methyl-pentanoyl-CoA, identified in the previously proposed mechanism for the conversion of two molecules of propionate into 2M2PE-CoA (supplemental Figs. S1 and S2) (16). The results were verified with both negative and positive controls. Negative controls that yielded no product or the intermediate included incubating the protein extract without substrates and incubating the substrates in buffer only. The positive controls which yielded both 2M2PE-CoA and putative 3-hydroxy-2-methyl-pentanoyl-CoA included incubating the entire protein extract, collected prior to FPLC separation, with the substrates, and incubating HepG2 cells in media supplemented with 100 μM propionate for 1 h (Fig. 2B).

To confirm the use of NADH/NADPH as a cofactor in the conversion of propionyl-CoA into 2M2PE-CoA, we monitored changes NADH/NADPH concentration by measuring the absorbance at 340 nm. Both NADH and NADPH absorb light at 340 nm, while the oxidized forms (NAD+ and NAPD+) do not (23) and FPLC samples 90–100 exhibited a decrease in NADH/NADPH concentration, correlating with the production of 2M2PE-CoA in these fractions (supplemental Fig. S1).

Analytical confirmation of the structure of 2M2PE-CoA

To confirm the identification of 2M2PE-CoA generated biologically, we produced a synthetic 2M2PE-CoA standard. LC-MS/HRMS data had matching coelution and fragmentation of the synthetic standard (Fig. 2A) with biologically generated 2M2PE-CoA from both HepG2 cells (Fig. 2B) and purified protein extract (Fig. 2C). For the HRMS, we observed a [MH]+ ion at m/z = 864.1811 which matches the theoretical m/z (864,1800) for C₂₇H₄₆N₂O₁₅P₂S (Δppm = 1.274) (supplemental Fig. S3). The MS/MS included the common fragment containing the acyl-group of the [MH-507]+ neutral loss distinctive to acyl-CoAs, as well as other fragments reflecting parts of the CoA moity and the acyl-group reported elsewhere (Fig. 2E) (24). Coelution was further confirmed by HepG2 cells incubated with propionate, 2M2PE, Δ⁵C₃ propionate reflecting a predominant +2 mass shift (incorporating 2 units of propionate), or a Δ⁵C₃ Δ¹⁵N₁ label on the pantothenate-derived moity of the CoA backbone reflecting a +4 mass shift (supplemental Fig. S4).

2M2PE-CoA forms from valine metabolism via propionyl-CoA in multiple murine tissues

Propionyl-CoA is an intermediate in a large number of metabolic pathways, including branched chain amino acid metabolism. Since our previous work has mostly used propionate directly as a tracer in ex vivo settings, we aimed to test the in vivo potential of this pathway while examining the potential of more diverse substrates to contribute carbon to 2M2PE-CoA. To understand the contribution of valine metabolism to potential formation of 2M2PE-CoA, we examined the abundance (pool size) and isotopolog enrichment from infused Δ⁵C-valine in mice from a previously described study (18). In murine tissues, acetyl-CoA was highly abundant in the liver (mean of 0.77 pmol/mg) and heart (mean of 0.50 pmol/mg), with relatively less abundance on a per mg of tissue basis in muscle (mean of 0.50 pmol/mg). Succinyl-CoA demonstrated a similar trend relative to acetyl-CoA across tissues but was less abundant than acetyl-CoA (Fig. 3B). Propionyl-CoA was highly variable across tissues, with molar amounts per mg tissue similar to succinyl-CoA (Fig. 3C).
Unfortunately, insufficient pancreatic tissue remained for analysis in this study.

To examine the fate of the infused $^{13}$C-valine, we determined the isotopolog enrichment of major short chain acyl-CoAs in the analyzed tissues. Isotopolog enrichment in acetyl-CoA revealed that only a relatively small amount of the acetyl-CoA pool in the examined tissue was derived from $^{13}$C-valine (Fig. 3D). This can likely be explained by both the relatively larger pool of acetyl-CoA as well as the other major substrates for acetyl-CoA including glucose and fatty acids. Isotopolog enrichment analysis of succinyl-CoA across tissues suggests some utilization of $^{13}$C-valine in muscle, with an average of 7.31% in M3 enrichment in TA (Fig. 3E). Propionyl-CoA was variably enriched across tissues for the M3 isotopolog, with the kidney being the most highly labeled tissue and containing a mean of 12.93% enrichment (Fig. 3F). Since propionyl-CoA is an intermediate of valine catabolism and all three carbons in the acyl-chain of propionyl-CoA can be derived from the carbon backbone of valine in this pathway, the combination of these labeling patterns strongly suggests breakdown of valine in the TCA cycle. These results strongly support the interpretation from Neinast, et al. (18) that the muscle is a large oxidizer of branched chain amino acids. This conclusion was robust even though we did not calculate enrichment values based on plasma valine labeling in a manner similar to Neinast since those calculations were already done for TCA cycle intermediates and we are interested primarily in the fate of the valine-derived propionyl-CoA. In sum, these results also suggest that valine is catabolized in the kidney to propionyl-CoA but is not (under the conditions studied) oxidized via the anaplerotic sequence into the TCA cycle through succinyl-CoA, which was described broadly as non-oxidative fates previously. Alternatively, this suggests that other substrates provide a sufficiently large proportion of the succinyl-CoA pool that labeling from valine was not observed. We were therefore interested if, especially in the kidney, the M3 enrichment would appear in 2M2PE since the tracer did not appear as enrichment in a substantial amount of the succinyl-CoA pool.

In previous studies, we had examined the formation of the novel metabolite 2M2PE from propionate ex vivo and in cells (16). Since we observed variable amounts of labeling into propionyl-CoA, we used this experiment to investigate the fate of valine-derived propionyl-CoA into 2M2PE-CoA. 2M2PE-CoA was
variably abundant across tissues (Fig. 4A) and displayed a similar trend to the relative abundance of propionyl-CoA (Fig. 4A vs. 3C). Calculated spearman rank indicated a correlation between the amounts of propionyl- and 2M2PE-CoA found in C57blk6 (r = 0.6429, P = 0.021), db/db (r = 0.7206, P < 0.001), and both mice groups when analyzed together (r = 0.734, P < 0.001) that varied by tissue (Fig. 4B–D).

Striking isotopolog enrichment of M3 of 2M2PE-CoA in the kidney (mean of 49.67%) suggested half the molar amount of the analyte in that tissue was partially derived from 13C-valine (Fig. 4E). We noted that this is higher than the enrichment of propionyl-CoA in the tissue, and a higher enrichment that the 13C-valine in plasma previously reported. This is partially explained by 2:1 stoichiometry of valine and propionyl-CoA to 2M2PE-CoA since there are two combinations of atoms that can make the M3 isotopologs of 2M2PE-CoA from one molecule of 13C5-valine or 13C3-propionyl-CoA. Alternatively, or in addition, there may be a
preferential fate for the propionyl-CoA formed from valine catabolism to form 2M2PE-CoA via compartmentalization or channeling. We were unable to obtain positional isotopomer information on the acyl-chain from the fragmentation spectra to resolve this. There was a correlation between the enrichment % of propionyl-CoA M3 and 2M2PE-CoA M3 + M6 in leptin-deficient diabetic db/db mice ($r = 0.6355, P = 0.001$) and when data for C57/blk6 control and db/db were combined ($r = 0.5443, P < 0.001$) (Fig. 4G–H). There was a weaker, not statistically significant association, when calculating this enrichment correlation in C57/blk6 mice. 2M2PE-CoA varies in amount and enrichment from valine catabolism across tissues and displays a similar trend to propionyl-CoA in normal and diabetic mice. A: Area under the curve and (E) isotopolog enrichment of 2M2PE-CoA labeling incorporating the $^{13}$C-label from infused $^{13}$C-valine in murine tissues. Spearman correlation ($r$) was calculated for the indicated relationships in (B and F) C57/blk6 (n=13), (C and G) db/db (n=22) and (D and H) both mouse groups combined (n=35). Strong significant correlations were found in all variables, with the expectation of (F) 2M2PE-CoA M3 + M6 and propionyl-CoA M3 enrichment % in normal mice ($r = 0.4542, P=0.120$). 2M2PE-CoA, trans-2-methyl-2-pentenoyl-CoA.
control mice \((r = 0.4542, P=0.120)\) (Fig. 4F). $^{13}$C-labeling of 2M2PE-CoA from $^{13}$C-propionate was also enriched in the heart and to a lesser extent BAT, the liver, and muscle (Fig. 4E). In BAT, heart, and liver tissues, isotopolog enrichment indicated that 2M2PE was variably but only somewhat derived from valine catabolism. gWAT showed a diffuse enrichment from M0 to M6; however, a major caveat of analysis in this tissue is the considerably lower relative abundance of 2M2PE-CoA in the tissue (supplemental Figs S5 and S6). The sum of this data suggests that 2M2PE generation and propionyl-CoA levels are strongly linked, with further work required to delineate the effects of other metabolic perturbations on this pathway. Additionally, the different patterns across tissues suggest other tissue-dependent pathways or compartmentalized metabolic pathways that may influence the preferential substrates and fates of this 3C pathway in vivo. The existence of M+3 suggests, and M+6 proves, that the 6-carbon acyl-chain from 2M2PE-CoA can come entirely from propionyl-CoA, recapitulating our previous observations ex vivo with propionate with an in vivo demonstration of this pathway from valine.

As reported in Neinstat, et al., during valine infusions, db/db mice achieved steady stable labeling at nearly twice the amount (40%–45%) compared to C57/blk6 control mice (22%–27%) to compensate for their larger body size (Fig. 5A–C) (18). This aligned with the conclusion that db/db mice showed reduced capacity of valine disposal compared to control mice and allowed a comparison of acyl-CoA labeling across the different valine labeling observed in the two strains. Increased % levels of valine labeling show an increased utilization of carbons into downstream intermediates for three-carbon metabolism succinyl-CoA M3, propionyl-CoA M3, and 2M2PE-CoA M3+M6. In controls, incorporation of endogenous valine was very low in succinyl-CoA M3 (0%–1%); however, diabetic mice showed a slight increase in enrichment at ~40–45% valine labeling in BAT, heart, kidney, and liver (0%–4%), and scattered distribution of gWAT (0%–60%) and TA (3%–45%) (Figs. 5A and S7). Propionyl-CoA M3 and 2M2PE-CoA M3+M6 displayed a similar trend to succinyl-CoA M3 with more noticeable changes (Fig. 5A–C). Formation of propionyl-CoA M3 and 2M2PE-CoA M3+M6 also increased in a dose-dependent manner with increasing valine treatment (Fig. 5A–C).

2M2PE-CoA is generated from propionate in human myocardial tissue

To test if the 3C–6C pathway extended to human tissue metabolism, we performed a time course study incubating heart tissues in Tyrode’s buffer with 5 mM unlabeled glucose and 100 μM $[^{13}$C3]-propionate as a stable isotope tracer. This resulted in similar labeling from 15, 30, and 60 min and distinct labeling patterns for acetyl-, succinyl-, propionyl-, and 2M2PE-CoAs (Fig. 6A–D). Metabolism via propionyl-CoA provides an anaplerotic pathway forming succinyl-CoA in the TCA cycle (8). If the formation of 2M2PE-CoA was dependent on entry of propionate into the TCA cycle, we might expect to see enrichment in repeating units of M1/M2 (e.g., M4) deriving from acetyl-CoA (C2 metabolism) instead of units of M3/M6 from propionyl-CoA. MID analysis of acetyl-CoA revealed no detectable incorporation of carbon from $[^{13}$C3]-propionate, although the relatively large pool size of acetyl-CoA does not preclude the possibility that a small amount of labeling did occur (Fig. 6A). Very little M1/M2 succinyl-CoA labeling (both approximately 1%–2% enriched) was observed; however, M3 labeling present in succinyl-CoA (around 3%–5%) likely arose from anaplerosis into the TCA cycle via propionyl-CoA.
For propionyl-CoA, heart tissues treated with \(^{13}\text{C}_3\)-propionate revealed the anticipated M3 enrichment (Fig. 6C). Area under the curve of the isotopologs of 2M2PE-CoA suggests that this molecule is not coming from C2 metabolism since labeling in M2 + M4 isotopologs is less than M3 + M6 suggesting 3C anabolism (Fig. 2D). This observation confirms incorporation of propionate into 2M2PE-CoA since M3/M6 labeling is detected throughout apparently healthy human heart ex vivo (Fig. 6B–D). The generation of the M5 and the M6 isotopologs of 2M2PE-CoA in the absence of acetyl-CoA M1 or M2 labeling confirms that the \(^{13}\text{C}_3\)-propionate is not required to first enter the TCA cycle or that the 2M2PE-CoA is derived by canonical fatty acid synthesis via acetyl-CoA.

**DISCUSSION**

Mammalian anabolic metabolism is traditionally thought to work in units of 1- and 2-carbons. It is believed that mammals lack the capability to utilize three-carbon units of propionate for anabolic reactions, instead shunting excess propionyl-CoA (through D-methylmalonyl-CoA then L-methylmalonyl-CoA) to generate succinyl-CoA as a precursor to other intermediates in the TCA cycle (8, 9). We show here that 3C metabolism occurs in intact human heart from propionate and in live conscious mice under physiological conditions from valine. We demonstrate that two molecules of propionyl-CoA derived from propionate or valine catabolism may condense to form a six-carbon 2M2PE-CoA. This replicates our previous findings with both \(^{13}\text{C}\)- and \(^2\text{H}\)-labeled propionate giving rise to labeling into 2M2PE-CoA that requires a stoichiometry of 2 propionate molecules without metabolism through acetyl-CoA or 1-carbon metabolites in multiple human and murine cell lines, as well as isolated human platelets (16). Importantly, the experiments with fractionated proteins demonstrates that this reaction occurs from propionyl-CoA, NAD(P)H, and the still unknown enzyme(s).

In humans, sources of propionate include the gut microbiota and propionate from food additives. As a food additive, propionate is used as an antimicrobial and is “generally regarded as safe”. Recently, consumption of this additive has been linked to deleterious metabolic effects. Tirosh et al. showed that propionate consumption increased endogenous glucose production leading to hyperinsulinemia via increased norepinephrine, glucagon, and fatty acid-binding protein 4 (FABP4 or aP2) in mice and humans (11). This is a concern, given the addition of propionate in foods, as well as compelling evidence that chronic hyperinsulinemia can drive obesity, the development of type 2 diabetes, and other metabolic abnormalities (25–27). Further elucidation of the 2M2PE-CoA pathway could benefit in unraveling the various metabolic effects of propionate in humans.
Nonoxidative fates of propionate are poorly understood in humans and this poses a challenge in the experimental use of propionate, studies of dietary fates of propionate, as well as the interpretation of pathological propionate metabolism. While oxidative fates of propionate can be quantitatively accounted for by examining tracing into the TCA cycle, nonoxidative fates remain comparatively unexplored. Thus, propionate is commonly used as an isotope tracer to examine TCA cycle metabolism due to tissue and context-specific utilization via anaerobiosis to succinyl-CoA. Accounting for nonoxidative fates, including but not necessarily limited to 2M2PE-CoA, may improve the interpretation and performance of propionate tracer models.

The propionyl-CoA to 2M2PE-CoA metabolic pathway may explain the plethora of branched chain fatty acids and unidentified metabolites that form in the blood and urine of PA patients (15). This route is of particular interest because it generates a relatively nonpolar but more acidic intermediate that can potentially be metabolized to a diversity of branched chain products which may alter the toxicity from high levels of propionic acid (16). Currently, elevated propionylcarnitine (C3) is the primary metabolic finding of PA at diagnosis by newborn screening (28). However, diagnosis by C3 is prone to false-positives, leading to significant diagnostic odyssey until secondary tests can be conducted (29). Furthermore, PA patients can enter metabolic crisis before newborn screening results are available or confirmed, thus earlier biomarkers of PA control are desirable (15). With understanding of 2M2PE and clinically observable products, we can identify biomarkers of excess propionic acid metabolism. Future work that identifies the enzymology of this pathway may be warranted to elucidate the functional consequences of metabolism of propionyl-CoA to 2M2PE-CoA.

CONCLUSION

Anabolic conversion of 3-carbon propionyl-CoA to 6-carbon 2M2PE-CoA occurs in vivo from valine. Conversion of propionate to 2M2PE-CoA was conserved in human hearts. Future work should elucidate the mechanism of control and enzymology responsible for this metabolic pathway.

Data availability

Data described is contained within the article and 2M2PE-CoA was added as Lipidmaps LMFA07050487 and updated in PubChemID Compound CID 121225619. 

Supplemental data

This article contains supplemental data (16, 20, 23).

Acknowledgments

The authors would like to thank Sanhka “Bobby” Basu for discussions in improving the article.

Author contributions


Author ORCIDs

David Bartee https://orcid.org/0000-0001-8090-4242
Donita C. Brady https://orcid.org/0000-0002-2786-2802
Zoltan Arany https://orcid.org/0000-0003-1368-2453
Nathaniel W. Snyder https://orcid.org/0000-0001-5643-8747

Funding and additional information

This work was funded by NIH grants T32-GM07229 to M. D. N., ADA fellowship 1-18-PDF-144 to S. T., ADA fellowship 1-17-PDF-076 to C. J., Intramural Research Program of NIH (ZIA BC011488-06) NIH grants HL094499 and DK107667 to Z. A., and NIH grants GM132261 and HD092630 to N. W. S. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest

The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations

2M2PE-CoA, trans-2-methyl-2-pentenoyl-CoA; acetyl-CoA, acetyl-coenzyme A; ACN, acetonitrile; BAT, brown adipose tissue; CV, column volume; gWAT, gonadal white adipose tissue; HepG2, Human hepatocellular carcinoma cells, MeOH, methanol; PA, propionic acidemia; TA, tibialis anterior muscle; THF, tetrahydrofuran.

Supplemental data

This article contains supplemental data (16, 20, 23).

REFERENCES

synthesis of odd-chain and even-chain fatty acids in 3T3-L1 adipocytes. PLoS One 10, e0145850